By spring 2017, most states had passed laws addressing when a biosimilar could be substituted for the product it resembled. What started as a fight over those laws had settled into a fairly uniform template, reflected in a reference chart of state biosimilar laws:
The early alarm about these laws proved partly overstated. They did not prevent substitution. What they did was add steps, and steps have a cost. That cost showed up as slower uptake rather than as blockage.
What the laws changed
A substitution law governs the handoff between prescribing and dispensing. It does not make every biosimilar interchangeable with the approved drug it resembles. It creates a pathway for substitution when the product carries the interchangeable designation, then sets conditions around that substitution: the prescriber can block it, and the pharmacist must record it and notify the prescriber.
A biosimilar can be approved without being eligible for substitution under the state template. Approval places a product on the market. The interchangeable designation places it in the substitution pathway. FDA’s biosimilars information describes the federal framework behind that designation.
For a patient, a prescription for one product does not necessarily lead to an automatic switch to a biosimilar. The product’s designation matters first. The state’s procedural requirements matter next. Even when substitution is permitted, the process involves communication and documentation that a simple dispensing decision would not require.
The rules therefore shape the practical friction around substitution. They do not, by themselves, decide whether a biosimilar will be available, preferred, or widely used.
Why the designation mattered more than the laws
The bigger limit on the substitution framework lay with the products themselves. Few biosimilars pursued the interchangeable designation at all. That kept those products outside the substitution pathway regardless of what state law permitted.
This explains why the fight over state legislation did not translate into widespread switching. A law can authorize a pharmacist to substitute a qualifying product, but it cannot create qualifying status for products that do not have it. If few products enter the pathway, the law has little opportunity to operate.
Two questions are easy to combine and should be kept apart. One is whether a biosimilar has been approved. The other is whether it can be substituted under the applicable rules. Approval adds a product to the market. Interchangeability determines whether it can use the substitution route.
For someone paying for medication, the distinction is practical. A lower-cost alternative may exist in the broader market without being something a pharmacist can dispense in place of the prescribed product. The availability of a biosimilar and the ability to substitute it are related, but they are not the same thing.
Uptake moved slowly for other reasons
Biosimilar approvals accumulated, but market share moved slowly. The larger explanation was contracting rather than state substitution law.
That matters because slow uptake can be misread. It may look as though legal restrictions stopped substitution, when the larger influence was the commercial structure around which products were selected and paid for. State rules added steps, and those steps had a cost. Contracting was the more important reason market share did not move quickly.
The result was a market in which legal permission existed more often than actual substitution. The template was in place, but the products eligible to use it were limited, and commercial arrangements shaped uptake. The laws had a real but limited effect. They set the process, while designation and contracting determined how often the process was used. The earlier analysis of state limits on biosimilar substitution addresses how those rules were expected to work.
The framework did not cover separate dispensing routes
Compounded GLP-1 preparations do not fit into this framework at all. They are not interchangeable versions of an approved drug, and they cannot be dispensed in place of one. FDA’s guidance on human drug compounding addresses that separate route.
A biosimilar substitution involves an approved product that has entered the interchangeability pathway. A compounded preparation is a separate route with separate rules, and that difference is the main point to understand before choosing between the two. A state biosimilar substitution law does not make a compounded GLP-1 preparation an interchangeable alternative, and a pharmacist cannot treat it as one simply because it is discussed as another option.
The provider comparison helps explain what that separate route is.